Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel: +47 21 07 81 60
E-mail:

Copyright/Disclaimer

List of DDDs for 3 years revision

The DDDs, which will be reviewed at the March 2023 meeting (3 year revision) are listed below. See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2023.

ATC code	ATC level name (INN/generic name)	DDD	Unit	Adm.route
D01BA03	fosravuconazole	0.1 ²⁾	g	O
N03AX25	cenobamate	0.2	g	O
A16AX12	trientine	0.45 ¹⁾	g	O
A10BG04	lobeglitazone	0.5	mg	O
L04AC17	tildrakizumab	1.11	mg	P
L04AC18	risankizumab	1.67	mg	P

J01DH56	imipenem, cilastatin and relebactam	2 ⁴⁾	g	P
N07BC01	buprenorphine	2.1	mg	P
B06AC05	lanadelumab	21.4	mg	P
J01DH52	meropenem and vaborbactam	3 ³⁾	g	P
A07EA06	budesonide	2	mg	SL
H04AA01	glucagon	3	mg	N
N05CD08	midazolam	5	mg	N
B01AX07	caplacizumab	10	mg	P
N05CD08	midazolam	10	mg	SL
H05BX05	calcifediol	30	mcg	O
B03AB10	ferric maltol	60	mg Fe³⁺	O
J01MA25	lascufloxacin	75	mg	O

1) expressed as trientine
2) expressed as ravuconazole
3) Refers to meropenem
4) Refers to imipenem

Last updated: 2022-12-19